Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
Evolus (NASDAQ: EOLS) has launched its 'Drop the F Word' campaign preceding the commercial release of Evolysse™, a new collection of injectable hyaluronic acid (HA) gels for treating moderate to severe facial wrinkles and folds. The campaign aims to eliminate the term 'filler' from aesthetic industry vocabulary, responding to consumer research indicating negative associations with unnatural, overfilled appearances.
The company introduces Cold-X™ technology, the first breakthrough in HA technology in over a decade, designed to better preserve the natural structure of the HA molecule. This innovative manufacturing process aims to deliver more natural-looking outcomes aligned with modern consumer expectations.
The initiative represents Evolus's strategic move to redefine industry terminology and advance the aesthetics experience, focusing on personalization, education, and natural-looking results.
Evolus (NASDAQ: EOLS) ha lanciato la campagna 'Drop the F Word' in vista del lancio commerciale di Evolysse™, una nuova linea di gel iniettabili a base di acido ialuronico (HA) per il trattamento delle rughe e delle pieghe facciali da moderate a profonde. La campagna mira a eliminare il termine 'filler' dal vocabolario dell'industria estetica, rispondendo a ricerche sui consumatori che associano questo termine a un aspetto innaturale e sovraccarico.
L'azienda presenta la tecnologia Cold-X™, la prima innovazione significativa nella tecnologia HA da oltre un decennio, progettata per preservare meglio la struttura naturale della molecola di HA. Questo processo produttivo innovativo vuole offrire risultati dall'aspetto più naturale, in linea con le aspettative moderne dei consumatori.
L'iniziativa rappresenta una mossa strategica di Evolus per ridefinire la terminologia del settore e migliorare l'esperienza estetica, puntando su personalizzazione, formazione e risultati dall'aspetto naturale.
Evolus (NASDAQ: EOLS) ha lanzado su campaña 'Drop the F Word' antes del lanzamiento comercial de Evolysse™, una nueva colección de geles inyectables de ácido hialurónico (HA) para tratar arrugas y pliegues faciales moderados a severos. La campaña busca eliminar el término 'filler' del vocabulario de la industria estética, respondiendo a investigaciones que muestran asociaciones negativas con apariencias poco naturales y sobrecargadas.
La empresa presenta la tecnología Cold-X™, el primer avance significativo en tecnología HA en más de una década, diseñada para preservar mejor la estructura natural de la molécula de HA. Este proceso de fabricación innovador busca ofrecer resultados con un aspecto más natural, acorde con las expectativas actuales de los consumidores.
La iniciativa representa un movimiento estratégico de Evolus para redefinir la terminología de la industria y avanzar en la experiencia estética, enfocándose en la personalización, la educación y resultados de apariencia natural.
Evolus (NASDAQ: EOLS)는 중등도에서 중증의 얼굴 주름 및 주름 개선을 위한 새로운 히알루론산(HA) 주사제 컬렉션인 Evolysse™의 상업적 출시를 앞두고 'Drop the F Word' 캠페인을 시작했습니다. 이 캠페인은 미용 업계에서 '필러(filler)'라는 용어를 없애고자 하며, 소비자 조사에서 비자연스럽고 과도하게 주입된 이미지와 연관된 부정적 인식을 반영한 것입니다.
회사는 10년 만에 처음 선보이는 HA 기술 혁신인 Cold-X™ 기술을 도입했습니다. 이 기술은 HA 분자의 자연 구조를 더 잘 보존하도록 설계되었으며, 혁신적인 제조 공정을 통해 현대 소비자의 기대에 부합하는 보다 자연스러운 결과를 제공합니다.
이 이니셔티브는 용어 재정립과 개인 맞춤화, 교육, 자연스러운 결과에 중점을 둔 미용 경험 향상을 위해 Evolus가 전략적으로 추진하는 움직임을 나타냅니다.
Evolus (NASDAQ : EOLS) a lancé sa campagne 'Drop the F Word' avant le lancement commercial de Evolysse™, une nouvelle gamme de gels injectables à base d'acide hyaluronique (AH) destinée au traitement des rides et plis du visage modérés à sévères. Cette campagne vise à supprimer le terme « filler » du vocabulaire de l'industrie esthétique, en réponse à des études consommateurs montrant des associations négatives avec un aspect artificiel et surchargé.
L'entreprise présente la technologie Cold-X™, la première avancée majeure dans la technologie AH depuis plus d'une décennie, conçue pour mieux préserver la structure naturelle de la molécule d'AH. Ce procédé innovant de fabrication vise à offrir des résultats au rendu plus naturel, en phase avec les attentes actuelles des consommateurs.
Cette initiative représente une démarche stratégique d'Evolus pour redéfinir la terminologie du secteur et faire progresser l'expérience esthétique, en mettant l'accent sur la personnalisation, la formation et des résultats au rendu naturel.
Evolus (NASDAQ: EOLS) hat seine Kampagne 'Drop the F Word' gestartet, noch vor der kommerziellen Markteinführung von Evolysse™, einer neuen Kollektion injizierbarer Hyaluronsäure (HA) Gele zur Behandlung von mittelschweren bis schweren Gesichtsfalten und -furchen. Die Kampagne zielt darauf ab, den Begriff 'Filler' aus dem Vokabular der ästhetischen Branche zu entfernen, als Reaktion auf Verbraucherforschung, die negative Assoziationen mit unnatürlichem, überfülltem Aussehen zeigt.
Das Unternehmen stellt die Cold-X™ Technologie vor, den ersten Durchbruch in der HA-Technologie seit über einem Jahrzehnt, entwickelt, um die natürliche Struktur des HA-Moleküls besser zu bewahren. Dieser innovative Herstellungsprozess soll natürlichere Ergebnisse liefern, die den modernen Erwartungen der Verbraucher entsprechen.
Die Initiative stellt einen strategischen Schritt von Evolus dar, die Terminologie der Branche neu zu definieren und das ästhetische Erlebnis weiterzuentwickeln, mit Fokus auf Personalisierung, Aufklärung und natürlich wirkende Resultate.
- First breakthrough in HA technology in over 10 years with proprietary Cold-X technology
- Strategic product differentiation addressing identified consumer concerns
- Expansion of product portfolio into HA injectable market
- Entering highly competitive aesthetic injectable market
- Success dependent on market acceptance of new branding strategy
Insights
Evolus's "Drop the F Word" campaign represents a calculated attempt to differentiate in the crowded injectable aesthetics market, though with uncertain financial impact. This pre-launch marketing initiative focuses on rebranding terminology rather than introducing revolutionary clinical benefits, which limits its immediate investment significance.
The strategic timing suggests Evolus is looking to position Evolysse™ as a premium offering in the $5+ billion global HA filler market. While the company claims their Cold-X™ technology is "the first breakthrough in HA technology in over a decade," the article lacks specific clinical data demonstrating superior performance over established products from market leaders like Allergan (Juvéderm) or Galderma (Restylane).
This rebranding approach appears designed to address the growing consumer resistance to overfilled aesthetics, which aligns with current market trends toward more natural-looking results. However, marketing campaigns rarely drive significant revenue shifts in the practitioner-influenced injectables segment without compelling clinical differentiation.
For investors, the upcoming Evolysse™ launch represents potential portfolio diversification beyond Evolus's neurotoxin product Jeuveau®, potentially reducing single-product dependency. However, entering the mature HA gel segment will require substantial marketing investment and faces entrenched competition from larger players with established practitioner relationships. Without pricing details, profit margin potential, or launch timeline, this announcement provides basis for revising financial projections.
The “Drop the F Word” campaign aims to reenergize the injectable HA category and address growing filler fatigue. Increasingly, consumers associate the term “filler” with unnatural results and an overfilled look, perceptions that no longer reflect the advancement of today’s products or consumer desires. In response, Evolus conducted in-depth research with customers and consumers to better understand these shifting attitudes. The insights were clear, “filler” is an outdated term and no longer serves the category. As a result, Evolus tested new ways to reframe the category and is introducing Evolysse™ as a collection of injectable hyaluronic acid gels, removing “filler,” the “F word,” from its vernacular. This approach better reflects the innovation behind the collection and the results consumers expect today.
“As aesthetic treatments evolve, the conversation around them must evolve too,” said David Moatazedi, President and Chief Executive Officer of Evolus. “With the 'Drop the F Word' campaign, we’re pushing the industry forward, replacing the outdated term 'filler' with a more modern, meaningful conversation centered around personalization, education, and natural-looking results. Evolysse™ isn’t just another filler, it’s the future of performance beauty.”
With the first breakthrough in HA technology in over a decade, Evolysse™ marks a new chapter in aesthetic injectables, moving beyond the traditional concept of “fillers” and toward a new standard of personalized, natural-looking outcomes. Evolysse™ is manufactured utilizing Cold-X™ technology, an innovative manufacturing process designed to better preserve the natural structure of the HA molecule. The result is a collection of injectable HA gels that deliver natural-looking outcomes and align with the evolving expectations of today’s aesthetic consumers.
Through this initiative, Evolus is inviting patients, practitioners, and the broader beauty industry to rethink how aesthetic treatments are discussed, embraced, and delivered. The campaign also underscores the company’s broader mission and modern approach to elevate the aesthetics experience, prioritizing confidence and informed decision-making across all stakeholders.
With Evolysse™, Evolus is not only launching an innovative injectable HA collection but also leading a cultural shift in how beauty treatments are perceived. This campaign and product launch together represent a commitment to advancing performance beauty that reflects the expectations of today’s beauty consumer.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc.
Cold-X™ is a trademark of Symatese Group S.A.S.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250415249207/en/
Evolus Contacts:
Investors:
Nareg Sagherian
Vice President, Head of Global Investor Relations and Corporate Communications
Tel: 248-202-9267
Email: ir@evolus.com
Media:
Email: media@evolus.com
Source: Evolus
FAQ
What is Evolysse and how does it differ from traditional fillers?
What is the significance of Evolus's 'Drop the F Word' campaign for EOLS investors?
How does Evolysse's Cold-X technology innovation impact the HA market?
What market need is EOLS addressing with Evolysse's launch?
